arrow
F

Francesca L. Mordant

university of melbourne
H指数:21
被引数:2,815

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2

COVID-19疫苗接种和突破性感染后,在初次感染者和康复者中观察到的抗体反应表明,这些反应对SARS-CoV-2的祖先毒株存在印迹现象。

MBIO
IF4.7
2025-12-010
PRE
Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial

一项利用第二代分子夹稳定前融合构象的严重急性呼吸综合征冠状病毒2刺突亚单位疫苗的安全性与免疫原性研究:一项在18-55岁成人中进行的随机、双盲、活性对照、I期临床试验

2025-12-010
PRE
The Platform Trial I n CO VID-19 Priming and BOO sting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old

VID-19启动和BOO sting (PICOBOO) 的平台试验: 在AZD1222启动的50-<70岁的个体中作为第二次加强剂 (第四剂) 施用的不同新型冠状病毒肺炎疫苗的免疫原性,反应原性和安全性

2024-12-011
OAAI
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
2023-12-015
OAAI
Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
2023-11-011
OAAI
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19

新型冠状病毒肺炎患者Anti-SARS-CoV-2抗体谱的纵向血清学比较研究

2023-08-021
OAAI
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

SARS-CoV-2受体结合域蛋白疫苗介导的对SARS-CoV-2相关变异的广泛免疫

2023-06-017
OAAI
Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities
2023-05-2913
OAAI
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release

巨噬细胞ACE2是SARS-CoV-2复制和随后的细胞因子反应所必需的,这些反应限制了病毒粒的持续释放。

2023-04-2522
PRE
Robust SARS-CoV-2 T cell responses with common TCRab motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
2023-04-0113
OAAI
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2 (vol 13, 889372, 2022)

Fc工程ACE2-Fc是一种有效的多功能剂靶向SARS-CoV2 (vol 13,889372,2022)

2023-01-100
OAAI
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

Fc工程ACE2-Fc是一种有效的多功能药物靶向SARS-CoV2

2022-07-287
OAAI
Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection

长读RNA测序鉴定SARS-CoV-2体外感染期间宿主转录本的聚腺苷酸化延伸和差异转录本使用

2022-04-067
OAAI
Comparison of Seroconversion in Children and Adults With Mild COVID-19
2022-03-0960
OAAI
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
2021-10-0160
OAAI